

1 **Clinical study**

2

3 Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density
4 lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention
5 trial

6

7 Yuichi Ikegami, MD, PhD^a, Ikuo Inoue, MD, PhD^{a,*}, Yasuhiro Takenaka, PhD^{a,b}, Daigo Saito,
8 MD^a, Mitsuhiko Noda, MD, PhD^a, Akira Shimada, MD, PhD^a

9

10 ^aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of
11 Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan

12 ^bDepartment of Physiology, Graduate School of Medicine, Nippon Medical School, 1-25-16
13 Nezu, Bunkyo, Tokyo 113-0031, Japan

14

15 *Corresponding author. Tel.: +81-49-276-1875; Fax: +81-49-276-1875; E-mail:

16 i1901018@saitama-med.ac.jp

17

18 Key words: anagliptin; dipeptidyl peptidase-4 inhibitor; low-density lipoprotein cholesterol;
19 lathosterol; glucagon-like peptide-1

20

21 Running Title: Reduction of lathosterol by anagliptin monotherapy

22

1 **Abstract**

2 *Background.* Anagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been shown to
3 decrease low-density lipoprotein cholesterol (LDL-C) levels in plasma.

4 *Aim of study.* The objective of our study is to elucidate the mechanisms responsible for
5 anagliptin-mediated improvements in high LDL-C levels (hyper-LDL-C-emia).

6 *Methods.* We prospectively examined the effects of anagliptin monotherapy on fasting plasma
7 lathosterol, sitosterol, and campesterol levels in patients with type 2 diabetes mellitus and
8 hyper-LDL-C-emia for 6 months. We examined 8 patients who did not use hypoglycemic or
9 lipid-lowering drugs, other than anagliptin, for 4 months before initiating the study. Serum
10 variables related to glucose and lipid metabolism were measured before and after the
11 treatment for 6 months and pre- and post-prandially using the cookie-loading test.

12 *Results.* After treatment, anagliptin monotherapy (n = 8) significantly decreased fasting
13 LDL-C (182.8 to 167.8 mg/dL, as mean values of before and after the treatment) and plasma
14 lathosterol levels (3.2 to 2.6 mg/dL); however, no significant changes were observed in fasting
15 sitosterol or campesterol levels. Furthermore, a significant increase ($p = 0.0012$) in the
16 change in 1-h post-prandial active glucagon-like peptide-1 (GLP-1) levels was observed after
17 anagliptin treatment. For all participants (n = 17), fasting plasma lathosterol levels were
18 negatively correlated with pre-prandial GLP-1 levels.

19 *Conclusion.* Anagliptin monotherapy may have a beneficial effect on lipid metabolism, which is
20 mediated by the inhibition of hepatic cholesterol synthesis, and not by the inhibition of intestinal lipid
21 transport.

22 Abstract word count: 233 (max 300 words)

23

24 **1. Introduction**

25 Dipeptidyl peptidase-4 (DPP-4) inhibitors increase the plasma levels of incretins,
26 such as glucagon-like peptide-1 (GLP-1), by selectively inhibiting DPP-4 and thereby

1 promoting insulin secretion, which then results in hypoglycemic effects in patients with type
2 2 diabetes mellitus (T2DM). The degree of insulin secreted by the pancreatic beta cells,
3 following the stimulation of incretins, is dependent on blood glucose levels. Therefore, the
4 risk of hypoglycemia by DPP-4 inhibitor treatments is lower than that by other diabetes
5 drugs, such as sulfonylureas (SUs). DPP-4 inhibitors are currently used worldwide, and each
6 DPP-4 inhibitor has different clinical features depending on the type of agent [1]. Similar to
7 other DPP-4 inhibitors, anagliptin decreases glycosylated hemoglobin (HbA1c) and plasma
8 glucose levels [2, 3]. It has been shown to achieve the strongest effect in increasing plasma
9 GLP-1 levels by administering a dose of 100-200 mg twice daily to patients with T2DM [4]. A
10 previous study has reported that anagliptin treatment decreases plasma low-density
11 lipoprotein cholesterol (LDL-C) levels [5]. Thus, in the present study, we examined the effects
12 of anagliptin on fasting plasma lathosterol, sitosterol, and campesterol levels in patients with
13 T2DM and hyper-LDL-C-emia for 6 months to elucidate the mechanisms that lead to
14 improvements in plasma LDL-C levels. Lathosterol is a whole-body cholesterol synthesis
15 marker in the liver, while sitosterol and campesterol (both plant sterols) are sterol absorption
16 markers in the intestines.

17

18 **2. Materials and Methods**

19 *2.1 Subjects*

20 The inclusion criterion of the present study was as follows: patients with poorly
21 controlled T2DM (HbA1c < 8.0% or 63mmol/mol) and an LDL-C level of more than 140 mg/dl.
22 Participating T2DM patients had inadequate glycemic and lipid control and were being
23 treated with dietary and exercise interventions. The participants aged between 20 and 80
24 years of males and females. Key exclusion criteria were as follows: 1) patients using
25 hypoglycemic agents (SUs, biguanides, alpha-glucosidase inhibitors, glinides, dipeptidyl
26 peptidase-4 inhibitors, insulin, and GLP-1 receptor agonists); 2) hypersensitivity to
27 anagliptin; 3) patients with severe diabetic ketoacidosis, diabetic coma/pre-coma, or type 1
28 diabetes; 4) patients with sepsis, those scheduled for surgery and who underwent surgery,

1 and those with severe trauma; 5) patients with severe renal dysfunction (serum creatinine
2 level > 2.4 mg/dl for male and > 2.0 mg/dl for female), and patients undergoing hemodialysis
3 or peritoneal dialysis; 6) female patients who were pregnant or suspected to be pregnant; and
4 7) patients deemed by the investigator to be ineligible for participation in the study.

5

6 *2.2. Study Protocol*

7 A dose of 100-200 mg of anagliptin was administered in the morning and in the evening. The
8 Institutional Review Board of Saitama Medical University Hospital approved the
9 experimental protocol. This was a single arm, non-randomized, open-label prospective study
10 with blinded assessors. The protocol was registered at the University Hospital Medical
11 Information Network (UMIN) on August 5, 2013, with the identification number
12 UMIN000011256. Patients who provided written informed consent were enrolled in the
13 pre-drug intervention phase for 4 months with only lifestyle interventions; this was done to
14 ensure that any observed effects with pharmacotherapy were attribute to anagliptin
15 monotherapy. We assessed the following parameters at the start of the pre-drug period: both
16 pre- and 1- and 2-h post-prandial blood levels of glucose; lipid, insulin, C-peptide, and
17 proinsulin levels; pre- and 1-h post-prandial active GLP-1 levels using the cookie-loading test
18 (CLT); and fasting plasma lathosterol, sitosterol, and campesterol levels. During this period,
19 6 patients dropped out because of the necessity for interventions other than anagliptin for
20 dyslipidemia or hyperglycemia. After the pre-drug intervention phase, patients received
21 anagliptin monotherapy for 6 months. During the last visit of this study, patients underwent
22 CLT again. To assess the effects of anagliptin monotherapy on lipid metabolism, patients
23 receiving drugs other than anagliptin were excluded from the main analysis.

24

25 *2.3. Measurements*

26 The metabolic parameters described above, including glucose and lipid levels, were measured
27 at SRL, Inc. (Tokyo, Japan). These data were obtained to investigate the effects of 6-month
28 anagliptin monotherapy on both pre- and 1- and 2-h post-prandial levels of blood glucose,

1 lipid, insulin using Lumipulse® PrestoInsulin (Fujirebio Inc., Tokyo, Japan), C-peptide using
2 Lumipulse® PrestoC-peptide (Fujirebio Inc., Tokyo, Japan), proinsulin using Human
3 Proinsulin RIA KIT (Millipore Cor., MA, USA), and pre- and 1-h post-prandial active GLP-1
4 levels using Glucagon-Like Peptide-1 (Active) ELISA KIT (Millipore Cor., MA, USA) in
5 participating patients after 6 months. Moreover, markers for cholesterol synthesis
6 (lathosterol) and absorption (sitosterol and campesterol) were determined using gas
7 chromatography, GC-2010 (Shimadzu Co., Ltd, Kyoto, Japan). Serum apoB-48 levels were
8 measured using Apo B-48 chemiluminescent enzyme immunoassay KIT (Fujirebio Inc.,
9 Tokyo, Japan); these levels reflect exogenous lipoproteins, such as chylomicrons, and their
10 remnants. LDL-C levels were calculated using the Friedewald equation because all patients
11 had triglyceride (TG) levels less than 400 mg/dl.

12

13 *2.4. CLT*

14 CLT was performed after overnight fasting using previously described methods at baseline
15 and at 6 months after starting anagliptin treatment. Patients were instructed to ingest a
16 cookie with water within 30 minutes: half of the cookie was to be eaten within 10 min and the
17 remainder within the last 20 min. Anagliptin was administered immediately after CLT. Time
18 measurements were started when half the cookie was ingested. Blood samples were obtained
19 at 0, 1, and 2 h after ingesting the cookie, which consisted of 75 g of carbohydrates, 25 g of fat,
20 and 8 g of protein, and 592 kcal of energy (Saraya Co., Ltd., Osaka, Japan).

21

22 *2.5. Data analysis*

23 The primary outcome was the change in LDL-cholesterol levels after 6 months. The
24 secondary outcome was changes in plasma lathosterol, sitosterol, and campesterol levels.
25 Data are presented as the mean \pm standard deviation (SD) of the parametric variables.
26 Differences before and after anagliptin treatment were examined using the paired Student's
27 *t*-test, and the significance was set at a *p*-value of less than 0.05. A sub-analysis of the
28 correlation between lathosterol and active GLP-1 levels was performed by Spearman's

1 correlation test using samples from the remaining 17 participating patients at the end of the
2 study. All analyses were performed using the Statistical Package for Social Association
3 Version 21.0 (SPSS Inc., Chicago, IL)

4

5 **3. Results**

6 Twenty-three patients with T2DM and hyper-LDL-C-emia were included in the study. Both
7 pre- and 1- and 2-h post-prandial levels of blood glucose, lipids, insulin, C-peptide, and
8 proinsulin; pre- and 1-h post-prandial active GLP-1 levels; and fasting plasma lathosterol,
9 sitosterol, and campesterol levels were measured. Six patients dropped out because of
10 worsening hyperlipidemia and/or hyperglycemia before the initiation of the anagliptin
11 treatment. Among the 17 patients who were followed until the end of the study, 1 patient
12 received additional treatment with 10-mg ezetimibe daily and 2 patients received 5-mg
13 pravastatin daily to manage hyperlipidemia. We mainly analyzed 8 patients for whom
14 therapeutic agents were not changed during the test period (Fig. 1). These 8 patients did not
15 use hypoglycemic agents, such as SUs, biguanides, alpha-glucosidase inhibitors, glinides,
16 thiazolidinedione, other DPP-4 inhibitors, sodium-glucose co-transporter 2 inhibitors, insulin,
17 and GLP-1 receptor agonists, and did not use oral drugs for hyperlipidemia including statins,
18 fibrates, and ezetimibe.

19 The demographics of these 8 patients are summarized in Table 1, and their
20 biochemical characteristics before and after anagliptin monotherapy are shown in Table 2.
21 After 6 months of anagliptin monotherapy, HbA1c levels significantly decreased in these 8
22 patients. Anagliptin monotherapy for 6 months significantly decreased fasting lathosterol
23 levels ($p < 0.05$), whereas no such significant changes were noted in fasting sitosterol or
24 campesterol levels (Table 2).

25 Plasma glucose, insulin, and proinsulin levels obtained before and after anagliptin
26 monotherapy using the CLT are shown in Figure 2. Plasma glucose and proinsulin levels
27 significantly decreased after 6 months of anagliptin monotherapy, whereas no significant
28 changes were noted in insulin levels. After 6 months of anagliptin monotherapy, glucose

1 levels at 1 and 2 h after the CLT reduced significantly; however, no significant changes were
2 noted in fasting glucose levels. Plasma insulin levels before and 1 and 2 h after the CLT did
3 not significantly increase by 6-months anagliptin monotherapy. However, proinsulin levels
4 were significantly decreased 2 h after the CLT. Plasma GLP-1 levels before and 1 h after the
5 CLT at the end of anagliptin monotherapy are shown in Figure 3. Post-prandial plasma
6 GLP-1 levels increased significantly following anagliptin monotherapy. After 6 months,
7 plasma TC and high-density lipoprotein cholesterol (HDL-C) levels before and after the CLT
8 were not significantly different. However, plasma TG and apoB-48 levels slightly increased
9 (Fig. 4). The value of LDL-C was calculated using the Friedewald method (from plasma TC,
10 TG, and HDL-C levels). After 6 months of anagliptin monotherapy, plasma LDL-C levels
11 before the CLT decreased significantly, but not at 1 or 2 h after the CLT (Fig. 5).

12 We examined the relationship between active GLP-1 and lathosterol, campesterol, or
13 sitosterol levels as a sub-analysis. Figure 6A shows a scatter plot of the relationship between
14 fasting active GLP-1 levels and fasting plasma lathosterol levels in all 17 patients at end of
15 the study. Since GLP-1 levels of 2.0 pmol/L or lower were not detectable, plots corresponding
16 to these levels were omitted from the figure. Similarly, Figures 6B and 6C show scatter plots
17 corresponding to the relationship between fasting active GLP-1 levels and fasting plasma
18 campesterol or sitosterol levels. A negative correlation was observed between fasting active
19 GLP-1 levels and fasting plasma lathosterol levels but not between the former and fasting
20 plasma campesterol or sitosterol levels. No correlation was noted between post-prandial
21 active GLP-1 levels and fasting plasma lathosterol, campesterol, and sitosterol levels at the
22 CLT (data not shown).

23

24 **4. Discussion**

25 The results of the present study are consistent with those of previous studies, showing that
26 DPP-4 inhibitors decrease LDL-C levels [6, 7]. Moreover, our results showed that anagliptin
27 significantly decreased fasting plasma lathosterol levels, whereas it did not significantly alter
28 fasting sitosterol or campesterol levels. Thus, anagliptin monotherapy may have reduced

1 cholesterol synthesis in the liver, but it did not appear to have reduced cholesterol absorption
2 in the intestines. Our results suggest that higher fasting active GLP-1 levels are associated
3 with lower fasting plasma cholesterol levels. However, a previous study by Juntti-Berggren
4 et al. [8] showed that continuous administration of GLP-1 to patients with T2DM did not
5 change LDL-C levels. GLP-1 analogs, when injected subcutaneously, directly flows into the
6 systemic circulation. In contrast, active GLP-1, which is elevated by DPP-4 inhibitor, is
7 secreted from L-cells in the ileum but enters the liver via the portal vein before entering the
8 systemic circulation. Therefore, endogenous GLP-1 may exert different effects on cholesterol
9 metabolism, whereas exogenous GLP-1 may not. A previous study has reported that
10 anagliptin administered twice a day increases active GLP-1 levels after dinner significantly
11 more than sitagliptin administered only once a day [4]. Administering DPP-4 inhibitors
12 twice a day may be more advantageous for lowering LDL-C levels than administering them
13 once a day. Although vildagliptin is also administered twice a day, its half-life is markedly
14 shorter than that of anagliptin, which might lead to different LDL-C lowering effects.
15 Therefore, further studies are warranted. The effect of GLP-1 on
16 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) activity in the liver is still unclear. In contrast,
17 the administration of anagliptin has been shown to suppress the expression of SREBP-2, a
18 transcription factor for cholesterol synthesis, and decrease LDL-C levels in LDL
19 receptor-knockout mice, a model for studying hyperlipidemia, using that mechanism of action.
20 Thus, the suppression of SREBP-2 by anagliptin appears to be one of the mechanisms
21 underlying the drug's LDL-C lowering effect [9].

22 Onoue et al. recently observed that anagliptin, in combination with other
23 hypoglycemic drugs, reduces fasting apoB-48 levels; hence, they proposed that anagliptin is
24 beneficial for lipid metabolism by acting via the inhibition of intestinal lipid transport [10].
25 This effect was particularly observed in previous studies that included the concomitant use of
26 SUs, which have significant hypolipidemic effects and hypoglycemic activity. It is, therefore,
27 possible that SUs masked the LDL-C-lowering effects of anagliptin, especially in long-term
28 treatments. Another study has showed that anagliptin therapy for 4 weeks decreases the

1 level of the cholesterol synthesis marker lathosterol without affecting the levels of cholesterol
2 absorption markers [11]. The present study differed from these studies with regard to the
3 following: 1) monotherapy was performed for long period of 6 months and 2) the relationship
4 between lathosterol and active GLP-1 levels was examined.

5 The present results are not consistent with previous findings, which showed that
6 DPP-4 inhibitors decrease post-prandial TG and apoB-48 levels after a fat-loading test in
7 patients with T2DM [12]. Our results showed contradictory results that anagliptin did not
8 decrease post-prandial TG or apoB-48 levels in patients with T2DM after the CLT (Fig. 4A
9 and 4B). As a limitation of the present study, the sample size was small, particularly for
10 determining secondary outcomes. However, the study population was homogeneous for
11 anagliptin monotherapy, thus ruling out any potential influence of antidiabetic and
12 antihyperlipidemic drugs. Another limitation is that the sub-analysis of the correlation
13 between active GLP-1 levels and lathosterol, campesterol or sitosterol includes the data of
14 withdrawals. Therefore, the sub-analysis does not accurately reflect the influence of
15 anagliptin alone.

16

17 **5. Conclusions**

18 Anagliptin monotherapy for 6months significantly decreased the levels of LDL-C and the
19 cholesterol synthesis marker lathosterol without affecting the levels of the cholesterol
20 absorption markers. Lathosterol levels were negatively correlated with fasting active GLP-1
21 levels.

22

23 **Acknowledgment**

24 The authors thank Ms. Sawako Sato for her technical and secretarial assistance.

25

26 **Funding**

27 This work was supported by an annual budget of Department of Endocrinology and Diabetes,
28 Saitama Medical University.

1

2 **Conflict of interest**

3 There are no conflicts of interest associated with this study.

4

5 **References**

6 [1] J. Gerich, "DPP-4 inhibitors: what may be the clinical differentiators?," *Diabetes Res Clin*

7 *Pract*, vol. 90, no. 2, pp. 131-140, 2010.

8 [2] K. Kaku, "Efficacy and safety of anagliptin add-on therapy in Japanese patients with type

9 2 diabetes - Placebo-controlled, double-blind, parallel-group study with an open-label,

10 long-term extension," *Jpn Pharmacol Ther*, vol. 40, no. 9, pp. 745-770, 2012.

11 [3] K. Kaku, "Efficacy and safety of long-term monotherapy with Anagliptin in Japanese

12 patients with type 2 diabetes - A multi-centre, randomized, open-label, parallel-group

13 study (administered before meals vs. after meals)," *Jpn Pharmacol Ther*, vol. 40, no. 9, pp.

14 733-744, 2012.

15 [4] H. Uchino, K. Kaku, "A novel dipeptidyl peptidase-4 inhibitor, anagliptin, improved the

16 daily blood glucose profile," *Jpn Pharmacol Ther*, vol. 40, no. 10, pp. 859-869, 2012.

17 [5] K. Kaku, "Effects of anagliptin on serum lipids in Japanese patients with type 2 diabetes -

18 A pooled analysis of long-term therapy with anagliptin," *Jpn Pharmacol Ther*, vol. 40, no.

19 9, pp. 771-784, 2012.

20 [6] S. A. Cha, Y. M. Park, J. S. Yun et al., "A comparison of effects of DPP-4 inhibitor and

21 SGLT2 inhibitor on lipid profile in patients with type 2 diabetes," *Lipids Health Dis*, vol.

- 1 16, no. 1, p. 58, 2017.
- 2 [7] M. Monami, C. Lamanna, C. M. Desideri, and E. Mannucci, "DPP-4 inhibitors and lipids:
3 systematic review and meta-analysis," *Adv Ther*, vol. 29, no. 1, pp. 14-25, 2012.
- 4 [8] L. Juntti-Berggren, J. Pigon, F. Karpe et al., "The antidiabetogenic effect of GLP-1 is
5 maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in
6 NIDDM patients," *Diabetes Care*, vol. 19, no. 11, pp. 1200-1206, 1996.
- 7 [9] W. Yano, N. Inoue, S. Ito et al., "Mechanism of lipid-lowering action of the dipeptidyl
8 peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice," *J*
9 *Diabetes Investig*, vol. 8, no. 2, pp. 155-160, 2017.
- 10 [10] T. Onoue, M. Goto, E. Wada et al., "Dipeptidyl peptidase-4 inhibitor anagliptin reduces
11 fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized
12 controlled trial," *PLoS One*, vol. 15, no. 1, p. e0228004, 2020.
- 13 [11] K. Aoki, T. Ijima, H. Kamiyama, K. Kamiko, and Y. Terauchi, "Anagliptin decreases
14 serum lathosterol level in patients with type 2 diabetes: a pilot study," *Expert Opin*
15 *Pharmacother*, vol. 16, no. 12, pp. 1749-1754, 2015.
- 16 [12] Y. Noda, T. Miyoshi, H. Oe et al., "Alogliptin ameliorates postprandial lipemia and
17 postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report,"
18 *Cardiovasc Diabetol*, vol. 12, p. 8, 2013.

19

20 **Figure legends**

1 **Figure 1. Flowchart of participant selection in this study**

2

3 **Figure 2. Changes in parameters assessed using cookie-loading test**

4 Plasma glucose (A), insulin (B), and proinsulin(C) levels. The conversion factor was as

5 follows: glucose (mmol/L) = glucose (mg/dL)/18.0; insulin (pmol/L) = insulin (μ IU/mL)/0.144.

6 * p < 0.05 versus before treatment.

7

8 **Figure 3. Assessing changes in active glucagon-like peptide-1 using**
9 **cookie-loading test**

10 * p < 0.05 versus before treatment.

11

12 **Figure 4. Assessing changes in parameters using cookie-loading test**

13 Triglyceride (A) and apoB-48 (B) levels. The conversion factor was as follows: triglyceride

14 (mmol/L) = triglyceride (mg/dL)/88.5.

15

16 **Figure 5. Assessing changes in low-density lipoprotein cholesterol using**
17 **cookie-loading test**

18 The conversion factor was as follows: cholesterol (mmol/L) = cholesterol (mg/dL)/38.6. * p <
19 0.05 versus before treatment.

20

21 **Figure 6. The correlation between fasting active glucagon-like peptide-1 and**
22 **lathosterol (A), campesterol (B), and sitosterol (C) at the end of this study**
23 **(n=17).**

24 The plots include data on withdrawals. Plots below the detection limit of (2.0pmol/L) plasma
25 GLP-1 were omitted. The figure presents a total of 15 plots.

26

27

28 **Table 1. Baseline demographics of eight patients receiving anagliptin**

1 **monotherapy.**

2 Data on age and body mass index are expressed as means \pm standard deviations.

3

4 **Table 2. Comparison of parameters of eight patients before and after treatment**
5 **with anagliptin monotherapy.**

6 Data are expressed as means \pm standard deviations, and are comparisons of changes between
7 baseline and at 6 months of treatment for eight patients. ^aWe used detection-limited value
8 (3.1 pmol/L) for one patient after 6 months of treatment. BMI, body mass index; FPG, fasting
9 plasma glucose; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C,
10 high-density lipoprotein cholesterol; TG, triglyceride. The conversion factor was as follows:
11 glucose (mmol/L) = glucose (mg/dL)/18.0; cholesterol (mmol/L) = cholesterol (mg/dL)/38.6;
12 triglyceride (mmol/L) = triglyceride (mg/dL)/88.5; insulin (pmol/L) = insulin (μ IU/mL)/0.144.




Figure 1






Figure 2




Figure 3





Figure 4




Figure 5






Figure 6

Table 1

Demographics (n=8)	
Female sex-no. of patients (%)	4 (50)
Age-year	68.1±6.7
Body mass index-kg/m ²	24.6±4.2

Table 2

Biochemical characteristics (n=8)			
	Baseline	6 months	<i>p</i>
BMI (kg/m ²)	24.6±3.9	24.8±4.4	0.5325
FPG (mg/dL)	129.8±13.5	120.6±9.8	0.1475
HbA1c (%)	6.5±0.3	6.1±0.1	0.0033
TC (mg/dL)	260.4±42.6	246.9±45.3	0.0306
LDL-C (mg/dL)	182.8±34.7	167.8±38.3	0.0159
HDL-C(mg/dL)	58.0±10.6	56.0±10.5	0.1819
TG (mg/dL)	97.8±30.8	115.3±44.8	0.1179
Insulin (μU/mL)	7.6±3.6	8.1±5.5	0.6530
Proinsulin (pmol/L) ^a	20.2±14.6	18.9±13.9	0.2733
Lathosterol (μg/mL)	3.2±1.0	2.6±0.5	0.0413
Sitosterol (μg/mL)	3.1±1.1	3.1±1.1	1.0000
Campesterol (μg/mL)	5.6±1.6	5.8±1.8	0.3459